Photocure ASA

Report Publication Announcement • Jun 10, 2020

Photocure ASA: Streaming details for AGM and announcement of sustainability report

Photocure ASA: Streaming details for AGM and announcement of sustainability report

Oslo, Norway, 10 June 2020: Photocure ASA (OSE:PHO) today announces the

company's first sustainability report, which will be presented at the Annual

General Meeting (AGM) at 17:00 CET. The AGM will be live streamed and Dan

Schneider, President & Chief Executive Officer, will provide a general company

update.

The Photocure Annual General Meeting will be held at Advokatfirmaet Selmer AS'

premises in Tjuvholmen allé 1, 0252 Oslo, Norway on 10 June 2020 at 17:00 CET.

Following the Covid-19 pandemic, shareholders have been encouraged to exercise

their shareholder rights without attending in person through advance voting or

by providing a proxy to the Chairman of the board of directors or the person he

authorizes within 5 June 16:00 CET. The AGM will be live streamed, and questions

can be submitted throughout the event. The AGM will be held in English and can

be followed at:

https://channel.royalcast.com/webcast/hegnarmedia/20200610_4/

Announces sustainability report

"In Photocure, we focus all our efforts and resources on delivering

transformative solutions to improve the lives of bladder cancer patients. We are

proud of our unique technology, making bladder cancer cells glow bright pink,

which to date has helped treat over 500 000 patients worldwide. The primary

growth geographies for Photocure are the U.S. and European markets with large

untapped market opportunities. Our highly regulated business has an economic,

social and environmental impact on our surroundings and stakeholders, most

importantly the positive contribution to the patients' lives, the economies and

the societies in which we operate. Today, we present our first ESG

(Environmental, Social and Governance) report and have set goals for how to

improve our work in the future. I hope this report will provide new insight for

our stakeholders about our response to the sustainability challenges and

opportunities for our business and society," says Dan Schneider, President &

Chief Executive Officer of Photocure.

Guided by the Euronext ESG guidelines and GRI Standards, Photocure has

implemented a process based on stakeholder inclusiveness and materiality to

ensure that Photocure reports on the most material topics for the company and

the industry. During the spring of 2020 Photocure has completed its first

materiality assessment and undertaken systematic stakeholder dialogue, although

simplified due to the effect of Covid-19 on stakeholder groups. The materiality

assessment will ensure that the reporting is aligned with the group's business

objectives, supports the strategy and minimizes risks.

The materiality assessment is focused around key sustainability topics, taking

into account the interests of stakeholders and civil society. They include the

quality and safety of Photocure's products, how they are produced and purchased,

as well as the working environment of its employees. As for the business and

risk minimization, the material topics include ethical conduct in business

relationships, in research and development and when working with personal data.

"For Photocure as a pharmaceutical company, I believe responsibility,

transparency and sustainability must be integrated in our business model and

strategy. For us, efficient, high-quality products produced, sold and used in a

responsible manner is what makes us a successful company, in addition to our

people and culture. Our values constitute key premises for the company, both

internally and externally. Photocure's mission is to deliver transformative

solutions to improve the lives of bladder cancer patients. We seek to do so in a

responsible way and we will continue to do our part to build a better future

based on the foundation of diversity, equality, respect and inclusion,"

Schneider concludes.

Photocure's ESG report for 2019 and the company presentation by Dan Schneider

are enclosed.

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Tel: + 1-609 759-6515

Email: ds@photocure.com

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, which makes

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO).  For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com